Date:      18.01.2023, 4.00 pm-5.00 pm CET

Venue:    Webinar, https://uni-koeln.zoom.us/meeting/register/tJ0qcOqhrDsrHNEGHb2qY1jLpi95Af5DBnB2

Host:       Vaccelerate

Mpox is a potentially serious disease caused by infection with the mpox virus. It can be spread through close, personal, often skin-to-skin contact. There are two types of vaccines available in the United States that can prevent mpox.
One of them, JYNNEOS™, is a live, replication-deficient MVA vaccine. It is licensed by the U.S. Food and Drug Administration (FDA) and approved as a two-dose series for the prevention of smallpox and mpox for people aged 18 years and older.
The CDC investigated how case numbers are decreasing when high-risk behavior changes and when people with a risk of being infected are vaccinated with one or two doses of the mpox vaccine.
In this webinar, Daniel Payne will present the CDC’s different study approaches on mpox vaccine safety and efficacy, report about differences of symptoms and hospitalization among vaccinated and unvaccinated persons and if there have been any safety concerns or adverse events regarding the use of JYNNEOS.
VACCELERATE, the EU funded clinical research network for the coordination & conduct of European vaccine trials is looking forward to hosting this webinar.
The webinar will be recorded and published on https://vaccelerate.eu/.